Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login

Current news

2018

12.10.2018 Response to the Public Accounts Committee (PAC) report into price increases in generic medicines
24.09.2018 FMD safety feature consultation response
24.08.2018 No-deal Brexit technical notices and reference products
23.08.2018 Response to government’s publication of technical notices on plans to regulate medicines in the event of a no-deal Brexit
23.08.2018 Response to the Secretary of State for Health’s letter to medicines Marketing Authorisation Holders
07.08.2018 Reaction to the Government’s publication of a consultation on changes to the statutory medicines pricing scheme
31.07.2018 Director General of the British Generic Manufacturers Association (BGMA) and British Biosimilars Association (BBA) Warwick Smith’s reaction to NHS Improvements study on the savings delivered from 10 medicines which have switched to generics or biosimilars
05.07.2018 Public Accounts Committee on concessionary pricing of generic medicines
21.06.2018 BGMA and BBA reaction to draft withdrawal agreement and SPCs
08.06.2018 BGMA reaction to the National Audit Office investigation into NHS spending on generic medicines in primary care
01.06.2018 Paul Fleming, technical director of the BGMA, commented on the Access to Medicines Report.
29.05.2018 Tim de Gavre takes up BGMA Chair role
17.05.2018 Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector
26.04.2018 BGMA reaction to King's Fund report on medicines spend
24.04.2018 Generic medicines manufacturers urged to signup now to SecurMed UK
23.03.2018 Statement in response to the EU Council ratifying the Brexit transition deal
21.03.2018 BGMA reaction to the Health and Social Care Committee’s Report on Brexit: medicines, medical devices and substances of human origin
23.02.2018 The Department of Health and Social Care’s report and recommendations into Medication and dispensing errors
22.02.2018 National Audit Office
19.01.2018 AMR Industry Alliance Progress press release
19.01.2018 AMR Industry Alliance Progress report

Highlights

24.09.2018 FMD safety feature consultation response 24.08.2018 No-deal Brexit technical notices and reference products 23.08.2018 Response to government’s publication of technical notices on plans to regulate medicines in the event of a no-deal Brexit 23.08.2018 Response to the Secretary of State for Health’s letter to medicines Marketing Authorisation Holders 07.08.2018 Reaction to the Government’s publication of a consultation on changes to the statutory medicines pricing scheme 31.07.2018 Director General of the British Generic Manufacturers Association (BGMA) and British Biosimilars Association (BBA) Warwick Smith’s reaction to NHS Improvements study on the savings delivered from 10 medicines which have switched to generics or biosimilars 05.07.2018 Public Accounts Committee on concessionary pricing of generic medicines 01.06.2018 Paul Fleming, technical director of the BGMA, commented on the Access to Medicines Report. 29.05.2018 Tim de Gavre takes up BGMA Chair role 17.05.2018 Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector 26.04.2018 BGMA reaction to King's Fund report on medicines spend 24.04.2018 Generic medicines manufacturers urged to signup now to SecurMed UK 23.03.2018 Statement in response to the EU Council ratifying the Brexit transition deal 19.01.2018 AMR Industry Alliance Progress press release 19.01.2018 AMR Industry Alliance Progress report 19.12.2017 Updated Statement on disruption to supply of generic medicines and concessionary pricing 14.12.2017 BREXIT Life Science Coalition Joint position paper media release 14.12.2017 UK Exiting from EU Life Science industry coalition position paper 01.12.2017 NHS England CCG guidance on routine prescribing 28.11.2017 Europe’s life science industry urges Brexit breakthrough 27.11.2017 Reaction to the Government’s Industrial Strategy White Paper 20.11.2017 Reaction to EMA decision 22.09.2017 BGMA reaction to the Government's transition plan after Brexit